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Introduction
Cerebral venous thrombosis (CVT) is a distinct form of 
stroke primarily affecting young- and middle-aged adults 
and is a commonly considered differential diagnosis in 
patients presenting with headache and/or neurological defi-
cit particularly in the context of established risk factors. In 
general, CVT has a relatively favourable long-term prog-
nosis but challenges remain regarding timely diagnosis and 
appropriate treatment selection, although a consensus of 
current published guidelines support the use of anticoagu-
lation. However, development of clinical prediction scores, 
and expanding knowledge of treatment efficacy, may help to 
further improve clinical management.
This month’s journal club explores three papers relating 
to CVT. The first paper describes a prospective study of 
the predictive value of clinical variables and D-dimer levels 
in patients with clinically possible CVT. The second paper 
compares endovascular treatment with medical management 
versus standard anticoagulation for severe CVT. The third 
paper examines the safety and efficacy of dabigatran etex-
ilate versus warfarin in patients with CVT.
Prediction of cerebral venous thrombosis 
with a new clinical score and D‑dimer levels
Clinical prediction scores incorporating D-dimer levels are 
widely used in the evaluation of patients with suspected 
deep venous thrombosis or pulmonary embolism. This paper 
describes the development of an equivalent clinical score for 
stratifying patients into groups with low, moderate and high 
probability of CVT, and increasing the score’s predictive 
value by adding D-dimer levels.
Between September 2009 and February 2016, adult 
patients presenting to the neurological emergency depart-
ments of the University Hospitals of Bern and Amsterdam 
with clinically possible CVT were evaluated by a trained 
neurologist and consented to participate in the study. Inclu-
sion criteria included one or more of isolated unexpected 
headache, headache with focal neurological deficits, head-
ache associated with seizure and/or unexplained papil-
loedema. Exclusion criteria comprised anticoagulation 
treatment prior to admission and deep venous thrombosis, 
pulmonary embolus, stroke or myocardial infarction in the 
3 months prior to admission. Baseline characteristics, demo-
graphic data, risk factors and clinical findings were recorded. 
Plasma samples for standard parameters and D-dimer levels 
were taken on admission and analysed by blinded laboratory 
investigators. Diagnosis of CVT was confirmed by MR and/
or CT venography.
359 adults were included in the final analysis, with 
94/359 (25.8%) having a confirmed CVT on neuroimaging. 
All baseline characteristics, demographic data, risk factors 
and clinical findings were compared between CVT versus 
non-CVT patients and analysed for statistical significance. 
Using multivariate logistical regression, six variables were 
identified as optimal estimates of CVT probability, and these 
defined the final CVT score with a maximum of 14 points. 
These included seizure at presentation (4 points), known 
thrombophilia (4 points), oral contraception (2 points), 
duration of symptoms greater than 6 days (2 points), worst 
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headache ever (1 point) and focal neurological deficit at 
presentation (1 point). In the final score, 0–2 points defined 
those with low CVT probability, 3–5 moderate probabil-
ity and 6–14 high probability. The score’s predictive value 
was enhanced by applying D-dimer cut-offs of greater than 
500ug/L and 675ug/L, respectively, to the low-, moderate- 
and high-probability groups. None of the patients with con-
firmed CVT in the study showed low clinical probability for 
CVT and D-dimers < 500ug/L.
Comment
This study presents a new clinical score which may be help-
ful for prediction of CVT. Strengths include the multicentre 
design, large sample size, and consideration of a number 
of risk factors and clinical findings for CVT. Limitations 
include the development of the score at tertiary centres for 
cerebrovascular disease and not in standard emergency set-
tings. This may explain the high rate of CVT in the study 
population. The exclusion of patients with a previous deep 
vein thrombosis or pulmonary embolus or those already 
established on anticoagulation may have ruled out a subset 
of patients with prothrombotic states presenting with a CVT. 
The score’s utility in standard emergency care departments 
has yet to be proved.
Heldner et al. (2020) Neurology https ://doi.org/10.1212/
WNL.00000 00000 00999 8
Effect of endovascular treatment 
with medical management vs standard care 
of severe cerebral venous thrombosis
This randomised clinical trial was conducted across eight 
hospitals in the Netherlands, China and Portugal between 
September 2011 and December 2017. Adult patients with 
radiologically confirmed CVT with high probability for poor 
outcome were included in the study. Risk factors for poor 
outcome were defined as the presence of at least one of men-
tal status disorders, Glasgow coma scale < 9, intracerebral 
haemorrhage, or thrombosis of the deep cerebral venous 
system. Exclusion criteria included thrombocytopenia, 
space-occupying lesion and clinical and radiological signs 
of impending trans-tentorial herniation.
Of 67 patients enrolled, 33 (49%) were randomised to 
receive endovascular treatment with standard medical care 
(intervention group) and 34 (51%) to receive guideline-based 
medical care (control group). Patients in the intervention 
group underwent endovascular treatment within 24 h of ran-
domisation. Intervention consisted of mechanical thrombec-
tomy, pharmacological thrombolysis or both, at the discre-
tion of the interventional radiologist. All patients in the 
intervention group received therapeutic dose heparin after 
endovascular treatment was completed. Patients randomised 
to the control group received therapeutic dose heparin as per 
international guidelines. All patients in the intervention and 
control group received long-term anticoagulation with vita-
min K antagonists for a variable duration of 3–12 months.
Primary end point was the proportion of patients who 
had recovered without disability at 12 months. Second-
ary end points were the proportion of patients with a good 
recovery at 6 and 12 months, and recanalization rates. Safety 
end points included symptomatic intracranial haemorrhage. 
Functional outcome was scored using the modified Rankin 
Scale by blinded clinicians. At 12 months of follow-up, 22 
intervention patients (67%) had achieved the primary end 
point compared with 23 control patients (68%) (relative risk 
ratio 0.99; 95% CI, 0.71–1.38). There was no statistically 
significant difference in mortality or frequency of sympto-
matic intracerebral haemorrhage between the intervention 
and control group. The study was prematurely terminated 
following an interim futility analysis.
Comment
This is the first randomised clinical trial relating to the effi-
cacy and safety of endovascular therapy on CVT. Strengths 
of the study include a diverse patient population and inclu-
sion of a number of risk factors for poor outcome. Limita-
tions include the small sample size such that the study was 
underpowered to detect differences between the intervention 
and control groups, and the exclusion of the sickest patients 
with CVT and impending herniation. The authors concede 
that at the time of the study, available techniques and devices 
to achieve optimal recanalization in patients may have been 
sub-optimal, and that future studies using more advanced 
techniques may identify better recovery rates.
Coutinho et al. (2020) AMA Neurol. Published online 
May 18, 2020. https ://doi.org/10.1001/jaman eurol 
.2020.1022
Safety and efficacy of dabigatran etexilate 
vs dose‑adjusted warfarin in patients 
with cerebral venous thrombosis
The objective of this exploratory randomised trial was to 
compare safety and efficacy of dabigatran, a direct throm-
bin inhibitor, with warfarin, a vitamin K antagonist, in the 
prevention of recurrent thrombo-embolic events in patients 
who have experienced a CVT. This multicentre trial was 
conducted between December 2016 and June 2018 at tertiary 
centres in nine countries in Asia and Europe.
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Adult patients with radiologically confirmed CVT were 
randomised 5–15 days after initial treatment to receive either 
Dabigatran 150 mg twice daily or Warfarin at a therapeu-
tic dose for 24 weeks. Primary outcome was the number 
of patients with major haemorrhage or new thromboem-
bolic event during the treatment trial. Secondary outcomes 
included recanalization rates assessed by MR venography.
120 patients were randomised equally to the 2 treatment 
groups. Baseline characteristics including demographics, 
neuroimaging findings, clinical signs and risk factors for 
CVT were well matched in both groups. 88% of patients 
in the dabigatran group and 93% in the warfarin group 
completed treatment over 24 weeks. All 120 patients were 
included in the final analysis. No recurrent venous thrombo-
embolic events were observed in either group. Three major 
bleeding events were noted: one (1.7%) case of intestinal 
bleeding in the dabigatran group and two (3.3%) subdural 
haemorrhages in the warfarin group. Cerebral recanalization 
was noted in 33 out of 55 patients (60%) in the dabigatran 
group (95% CI, 45.9–73.0) and in 35 out of 52 patients 
(67.3%) in the warfarin group 95% CI, 52.9–79.7).
Comment
This was an exploratory trial demonstrating low risk of 
recurrent venous thromboembolism and of clinically rel-
evant bleeding with either dabigatran or dose-adjusted war-
farin in the study population. However, due to the small sam-
ple population and the low frequency of recurrent venous 
thromboembolism after CVT, the study was not powered 
to detect non-inferiority between the two treatment groups.
Ferro et al. JAMA Neurol. 2019; 76(12):1457–1465
Conclusion
The first paper outlines the development of a scoring system 
which could be utilised as a pre-test score in the clinical 
assessment of suspected CVT. The second and third papers 
demonstrate encouraging work regarding the efficacy and 
safety of interventional and oral treatments for CVT. Further 
study on the efficacy of endovascular treatment for CVT 
using newer techniques and devices is desirable, and may 
prove of benefit to patients with severe CVT. Larger scale 
studies are required to demonstrate the equivalence of direct-
thrombin inhibitors as an alternative means of anticoagula-
tion in patients with CVT.
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